What’s in Gossamer Bio, Inc. (GOSS) After Today’s Huge Decline?

The stock of Gossamer Bio, Inc. (NASDAQ:GOSS) is a huge mover today! The stock decreased 9.80% or $2.14 during the last trading session, reaching $19.74. About 280,764 shares traded or 0.61% up from the average. Gossamer Bio, Inc. (NASDAQ:GOSS) has 0.00% since September 13, 2018 and is . It has by 0.00% the S&P500.
The move comes after 6 months negative chart setup for the $1.34 billion company. It was reported on Sep, 13 by Barchart.com. We have $18.16 PT which if reached, will make NASDAQ:GOSS worth $106.80 million less.

Analysts await Gossamer Bio, Inc. (NASDAQ:GOSS) to report earnings on November, 14. After $-0.74 actual earnings per share reported by Gossamer Bio, Inc. for the previous quarter, Wall Street now forecasts -4.05 % EPS growth.

More notable recent Gossamer Bio, Inc. (NASDAQ:GOSS) news were published by: Businesswire.com which released: “Gossamer Bio to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019 – Business Wire” on August 05, 2019, also Nasdaq.com with their article: “Nasdaq’s Head of Healthcare Listings Shares 2019 Biopharma IPO Recap – Nasdaq” published on July 02, 2019, Nasdaq.com published: “Tis the season for big biotechs: Gossamer Bio files for a $265 million IPO – Nasdaq” on December 21, 2018. More interesting news about Gossamer Bio, Inc. (NASDAQ:GOSS) were released by: Gurufocus.com and their article: “Seth Klarman’s Small Biotech Holdings – GuruFocus.com” published on August 30, 2019 as well as Benzinga.com‘s news article titled: “28 Healthcare Stocks Moving In Today’s Pre-Market Session – Benzinga” with publication date: July 26, 2019.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company has market cap of $1.34 billion. It is developing GB001, an oral antagonist that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications. It currently has negative earnings. The firm was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.